Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.8% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2876
Pyxis Oncology
PYXS
$193M
| $460K | ﹤0.01% |
417,822
-164,314
| -28% | -$185K |
|
2877
Rockwell Medical
RMTI
$28.5M
| $459K | ﹤0.01% |
54,175
+8,875
| +20% | +$90.5K |
|
2878
Tompkins Financial
TMP
$1.45B
| $459K | ﹤0.01% |
7,313
-117
| -2% | -$7.12K |
|
2879
Outset Medical
OM
$92.5M
| $458K | ﹤0.01% |
23,860
-17,346
| -42% | -$271K |
|
2880
Union Bankshares
UNB
$109M
| $457K | ﹤0.01% |
17,158
-1,074
| -6% | -$32.7K |
|
|
GHG
2881
GreenTree Hospitality
GHG
$116M
| $455K | ﹤0.01% |
223,189
+8,336
| +4% | +$17.5K |
|
2882
Orchestra BioMed
OBIO
$247M
| $454K | ﹤0.01% |
+169,400
| New | +$494K |
|
2883
WidePoint Corp
WYY
$103M
| $453K | ﹤0.01% |
132,600
-44,798
| -25% | -$161K |
|
2884
Protara Therapeutics
TARA
$223M
| $452K | ﹤0.01% |
149,200
+19,800
| +15% | +$68.3K |
|
|
ADAP
2885
DELISTED
Adaptimmune Therapeutics
ADAP
| $451K | ﹤0.01% |
1,882,860
+69,000
| +4% | +$18.4K |
|
2886
First Financial Bancorp
FFBC
$3.58B
| $451K | ﹤0.01% |
18,600
-11,937
| -39% | -$283K |
|
|
SION
2887
Sionna Therapeutics
SION
$2.22B
| $451K | ﹤0.01% |
+26,000
| New | +$341K |
|
2888
Nautilus Biotechnolgy
NAUT
$129M
| $449K | ﹤0.01% |
619,906
+319,450
| +106% | +$240K |
|
2889
OptimumBank Holdings
OPHC
$113M
| $449K | ﹤0.01% |
100,400
-16,857
| -14% | -$72.7K |
|
2890
Hooker Furnishings Corp
HOFT
$160M
| $449K | ﹤0.01% |
42,400
-7,400
| -15% | -$71.5K |
|
2891
BitFuFu
FUFU
$220M
| $448K | ﹤0.01% |
138,833
+118,333
| +577% | +$438K |
|
2892
Holley
HLLY
$332M
| $448K | ﹤0.01% |
223,900
+52,000
| +30% | +$110K |
|
|
STKL
2893
DELISTED
SunOpta
STKL
| $447K | ﹤0.01% |
+77,047
| New | +$405K |
|
2894
Jerash Holdings
JRSH
$59.7M
| $445K | ﹤0.01% |
135,740
+30,860
| +29% | +$97.2K |
|
|
ZYXI
2895
DELISTED
Zynex
ZYXI
| $444K | ﹤0.01% |
172,262
+22,000
| +15% | +$49.8K |
|
2896
WisdomTree US LargeCap Dividend Fund
DLN
$6.3B
| $444K | ﹤0.01% |
5,400
-9,400
| -64% | -$734K |
|
|
AUNA
2897
Auna
AUNA
$389M
| $443K | ﹤0.01% |
71,500
+25,913
| +57% | +$174K |
|
2898
Vanguard Core Bond ETF
VCRB
$7.17B
| $442K | ﹤0.01% |
+5,700
| New | +$437K |
|
2899
Vera Bradley
VRA
$99.2M
| $442K | ﹤0.01% |
199,940
-71,300
| -26% | -$147K |
|
|
SGMA
2900
DELISTED
Sigmatron International
SGMA
| $442K | ﹤0.01% |
148,487
-39,794
| -21% | -$79.8K |
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.